Acquirers Offer to Buy 26% Stake in Colinz Laboratories Ltd for up to ₹3.53 Crore

Acquirers Offer to Buy 26% Stake in Colinz Laboratories Ltd for up to ₹3.53 Crore​

A consortium of individuals, comprising Annjana Dugar, Likhitta Dugar, and Antariksh Dugar, along with Padam Dugar (Person Acting In Concert), has launched a mandatory Open Offer for the public shareholders of Colinz Laboratories Limited. The offer aims to acquire up to 26% of the company’s voting share capital.

The acquisition is part of an overarching strategy by the group to take control and gain management oversight of the Target Company following a prior transaction.

Key Details of the Open Offer​

The Acquirers have set the offer price at ₹54 per equity share, providing cash consideration for all accepted shares. The total potential maximum consideration for this Open Offer is up to ₹3,53,68,164/- (Rupees Three Crore Fifty Three Lakh Sixty Eight Thousand One Hundred Sixty Four only).

Key details of the public offer are summarized below:

Strategic Acquisition and Financial Backing​

The mandatory Open Offer follows a substantial acquisition of shares executed through a Share Purchase Agreement (SPA) dated June 18, 2026. Under the SPA, the Acquirers committed to acquire 8,70,500 Equity Shares from Vijaya Mani, which represented 34.56% of the Total Voting Share Capital at a price of ₹50/- per share, for a consideration of ₹4,35,25,000/-.

The acquisition allows the Acquirers and PAC to assume control of the Target Company in accordance with relevant regulations upon closing the SPA transaction. The post-offer holding, assuming full acceptance of shares from all sources (SPA and Open Offer), is projected to reach 75.56% of the company’s voting share capital.

The Acquirers have ensured financial readiness for the acquisition. They deposited ₹89,00,000/- into an escrow account with ICICI Bank Limited. This deposit represents more than 25% of the offer consideration payable to Public Shareholders, confirming the Acquirers’ commitment and capability to fulfill their obligations under the Open Offer.

Company Overview​

Colinz Laboratories Ltd., which is listed on BSE (Scrip Code: 531210), is involved in manufacturing, marketing, and exporting pharmaceutical formulations. The company’s product portfolio includes allopathic, ayurvedic, and nutraceutical formulations across various dosage forms, catering to therapeutic segments such as gynaecology, cardiology, and gastroenterology.

As per the latest audited financial statements for the year ended March 31, 2026:

Offer Conditions and Compliance​

The Open Offer is non-conditional, meaning no minimum level of acceptance is required from the public shareholders. The Acquirers affirmed that they possess adequate financial resources and have firm financial arrangements in place to meet all obligations related to the Open Offer.

The tendering period for the Equity Shares will commence on August 11, 2026, and close on August 24, 2026. The identified date for determining eligible shareholders is July 28, 2026.

Key Personnel in the Acquisition Group​

The Acquirers include Annjana Dugar (Acquirer 1), Likhitta Dugar (Acquirer 2), and Antariksh Dugar (Acquirer 3). Padam Dugar serves as the Person Acting In Concert (PAC). The group has confirmed that they are not prohibited by SEBI from dealing in securities, nor do they have any pending proceedings related to the securities market.

Stock Price Movement​

At the close of trade on Friday, Colinz Laboratories Ltd shares settled at ₹77.55, suffering a 5.00% decline from previous closing prices. The stock remained locked throughout the day as its intraday high and low were identical at this single price point.